• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Orthofix Medical Inc.

    2/12/24 6:06:37 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    SC 13G 1 tm245464d13_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Orthofix Medical Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.10 par value per share

     

    (Title of Class of Securities)

     

    68752M108

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    (Page 1 of 8 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    CUSIP No. 68752M108

     

    13G Page 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    3,665,000 shares of Common Stock

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    3,665,000 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,665,000 shares of Common Stock

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.97%

     

    12

    TYPE OF REPORTING PERSON

    PN, IA

     

           

     

     

     

    CUSIP No. 68752M108

     

    13G Page 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    3,665,000 shares of Common Stock

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    3,665,000 shares of Common Stock

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,665,000 shares of Common Stock

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.97%

     

    12

    TYPE OF REPORTING PERSON

    IN

     

           

     

     

     

    CUSIP No. 68752M108

     

    13G Page 4 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Orthofix Medical Inc. (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 3451 Plano Parkway, Lewisville, Texas 75056.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, $0.10 par value per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      68752M108

     

     

     

     

    CUSIP No. 68752M108

     

    13G Page 5 of 8 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
           
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
           
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
           
      (e) 🗷 An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
           
      (g) 🗷 Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
           
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
           

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 36,756,607 shares of Common Stock outstanding as of November 6, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 8, 2023.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

     

     

     

     

    CUSIP No. 68752M108

     

    13G Page 6 of 8 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.
       

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 68752M108

     

    13G Page 7 of 8 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: February 12, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

     

    CUSIP No. 68752M108

     

    13G Page 8 of 8 Pages

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    DATED: February 12, 2024

     

    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

    Get the next $OFIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Global Orthopedics Fisher Patrick sold $28,363 worth of shares (1,996 units at $14.21), decreasing direct ownership by 6% to 30,116 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    8/20/25 4:08:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    7/7/25 5:43:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Finegan Michael was granted 26,087 shares, increasing direct ownership by 83% to 57,391 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/23/25 4:19:38 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Orthofix Medical Inc.

    10-Q - Orthofix Medical Inc. (0000884624) (Filer)

    8/5/25 7:05:06 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    8/5/25 7:03:36 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    6/20/25 9:00:28 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    7/7/25 5:43:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/5/25 5:11:05 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

    4/A - Orthofix Medical Inc. (0000884624) (Issuer)

    5/14/25 4:34:50 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Orthofix with a new price target

    Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

    1/22/25 7:47:50 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix upgraded by Stifel with a new price target

    Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

    11/8/24 8:23:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix upgraded by ROTH MKM with a new price target

    ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

    5/8/24 6:31:28 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orthofix Reports Second Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs, and pro forma net sales of $200.7 million, excluding sales from M6® discs, representing an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to second quarter 2024 U.S. Spine

    8/5/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference

    Wednesday, August 13, 2025 at 9:00 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 13, 2025 at 9:00 am Eastern Time. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. Or

    7/16/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Second Quarter 2025 Financial Results

    Company to Host Conference Call on Tuesday, August 5, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 4830464. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Info

    7/15/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Financials

    Live finance-specific insights

    View All

    Orthofix Reports Second Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs, and pro forma net sales of $200.7 million, excluding sales from M6® discs, representing an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to second quarter 2024 U.S. Spine

    8/5/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Second Quarter 2025 Financial Results

    Company to Host Conference Call on Tuesday, August 5, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 4830464. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Info

    7/15/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Reports First Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

    5/6/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

    SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

    11/14/24 5:20:27 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Orthofix Medical Inc.

    SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

    SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    4/22/24 5:00:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Vickie Capps to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

    3/12/25 8:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

    8/15/24 5:52:00 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Names Stephanie Walsh Chief Human Resources Officer

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

    7/16/24 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care